Literature DB >> 34070471

Carcinogenesis of Triple-Negative Breast Cancer and Sex Steroid Hormones.

Naoko Honma1, Yoko Matsuda2, Tetuo Mikami1.   

Abstract

Triple-negative breast cancer (TNBC) lacks an effective treatment target and is usually associated with a poor clinical outcome; however, hormone unresponsiveness, which is the most important biological characteristic of TNBC, only means the lack of nuclear estrogenic signaling through the classical estrogen receptor (ER), ER-α. Several sex steroid receptors other than ER-α: androgen receptor (AR), second ER, ER-β, and non-nuclear receptors represented by G-protein-coupled estrogen receptor (GPER), are frequently expressed in TNBC and their biological and clinical importance has been suggested by a large number of studies. Despite the structural similarity between each sex steroid hormone (androgens and estrogens) or each receptor (AR and ER-β), and similarity in the signaling mechanisms of these hormones, most studies or reviews focused on one of these receptors, and rarely reviewed them in a comprehensive way. Considering the coexistence of these hormones and their receptors in TNBC in a clinical setting, a comprehensive viewpoint would be important to correctly understand the association between the carcinogenic mechanism or pathobiology of TNBC and sex steroid hormones. In this review, the carcinogenic or pathobiological role of sex steroid hormones in TNBC is considered, focusing on the common and divergent features of the action of these hormones.

Entities:  

Keywords:  G-protein-coupled estrogen receptor (GPER); androgen; androgen receptor; estrogen; estrogen receptor-beta; sex steroid hormones; triple-negative breast cancer (TNBC)

Year:  2021        PMID: 34070471     DOI: 10.3390/cancers13112588

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  102 in total

1.  Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.

Authors:  Aristomenis Anestis; Panagiotis Sarantis; Stamatios Theocharis; Ilianna Zoi; Dimitrios Tryfonopoulos; Athanasios Korogiannos; Anna Koumarianou; Evangelia Xingi; Dimitra Thomaidou; Michalis Kontos; Athanasios G Papavassiliou; Michalis V Karamouzis
Journal:  J Cancer Res Clin Oncol       Date:  2019-02-25       Impact factor: 4.553

2.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

Review 3.  Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

Authors:  Carsten Denkert; Cornelia Liedtke; Andrew Tutt; Gunter von Minckwitz
Journal:  Lancet       Date:  2016-12-07       Impact factor: 79.321

4.  Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.

Authors:  Sewha Kim; Byung-In Moon; Woosung Lim; Sanghui Park; Min Sun Cho; Sun Hee Sung
Journal:  Clin Breast Cancer       Date:  2018-03-23       Impact factor: 3.225

5.  Significance of aromatase activity in human breast cancer.

Authors:  W R Miller; R A Hawkins; A P Forrest
Journal:  Cancer Res       Date:  1982-08       Impact factor: 12.701

6.  Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Authors:  Ayca Gucalp; Sara Tolaney; Steven J Isakoff; James N Ingle; Minetta C Liu; Lisa A Carey; Kimberly Blackwell; Hope Rugo; Lisle Nabell; Andres Forero; Vered Stearns; Ashley S Doane; Michael Danso; Mary Ellen Moynahan; Lamia F Momen; Joseph M Gonzalez; Arooj Akhtar; Dilip D Giri; Sujata Patil; Kimberly N Feigin; Clifford A Hudis; Tiffany A Traina
Journal:  Clin Cancer Res       Date:  2013-08-21       Impact factor: 12.531

7.  The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.

Authors:  Yan Shen; Fang Yang; Wenwen Zhang; Wei Song; Yuxiu Liu; Xiaoxiang Guan
Journal:  Cell Physiol Biochem       Date:  2017-10-23

8.  ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.

Authors:  Igor Bado; Fotis Nikolos; Gayani Rajapaksa; Jan-Åke Gustafsson; Christoforos Thomas
Journal:  Oncotarget       Date:  2016-03-22

9.  ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1.

Authors:  Wei Song; Lin Tang; Yumei Xu; Qian Sun; Fang Yang; Xiaoxiang Guan
Journal:  J Exp Clin Cancer Res       Date:  2017-06-05

10.  GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.

Authors:  Zhiqiang Mo; Manran Liu; Fangfang Yang; Haojun Luo; Zhenhua Li; Gang Tu; Guanglun Yang
Journal:  Breast Cancer Res       Date:  2013-11-29       Impact factor: 6.466

View more
  1 in total

1.  CmPn signaling networks in the tumorigenesis of breast cancer.

Authors:  Mellisa Renteria; Ofek Belkin; David Jang; Justin Aickareth; Muaz Bhalli; Jun Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.